91 related articles for article (PubMed ID: 3887443)
21. [Long-term clinical experience with clozapine].
Gelly F; Chambon O; Marie-Cardine M
Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
[TBL] [Abstract][Full Text] [Related]
22. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
23. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
[TBL] [Abstract][Full Text] [Related]
24. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
25. The use of depot neuroleptics: clinical experience in the United States.
Kane JM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
Lee MS; Ko YH; Lee SH; Seo YJ; Kim SH; Joe SH; Han CS; Lee JH; Jung IK
Hum Psychopharmacol; 2006 Aug; 21(6):399-407. PubMed ID: 16915580
[TBL] [Abstract][Full Text] [Related]
27. Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse.
Heresco-Levy U; Greenberg D; Lerer B; Dasberg H; Brown WA
Isr J Psychiatry Relat Sci; 1995; 32(4):268-75. PubMed ID: 8641856
[TBL] [Abstract][Full Text] [Related]
28. [Clinical observations of treatment with Lyorodin-depot (Jenapharm)].
Pirozynski T; Chiriţă V; Cosmovici N; Offenberg C; Chiriac ME; Marinescu V; Cojocaru M; Berlescu M; Mungiu A
Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):501-9. PubMed ID: 2700035
[TBL] [Abstract][Full Text] [Related]
29. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
Bralet MC; Yon V; Loas G; Noisette C
Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
[TBL] [Abstract][Full Text] [Related]
30. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Stanković Z; Britvić D; Vuković O; Ille T
Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
[TBL] [Abstract][Full Text] [Related]
31. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R
Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445
[No Abstract] [Full Text] [Related]
32. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
Abuzzahab FS; Zimmerman RL
J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
[TBL] [Abstract][Full Text] [Related]
33. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
Jain RC; Ananth JV; Lehmann HE; Ban TA
Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
[No Abstract] [Full Text] [Related]
34. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
35. [Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
Steiner S
Psychiatr Clin (Basel); 1980; 13(3-4):165-78. PubMed ID: 7244281
[TBL] [Abstract][Full Text] [Related]
36. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
37. [Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)].
Balon R; Kabesh Ia; Papezhova G
Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(1):116-8. PubMed ID: 6121437
[TBL] [Abstract][Full Text] [Related]
38. The dysphoric syndrome in schizophrenia and its implications for relapse.
Hirsch SR; Jolley AG
Br J Psychiatry Suppl; 1989 Jul; (5):46-50. PubMed ID: 2690890
[No Abstract] [Full Text] [Related]
39. Clinical experience with fluphenazine decanoate in the treatment of patients with long-standing chronic schizophrenia.
Christodoulidis H; Frangos H
Curr Ther Res Clin Exp; 1975 Jul; 18(1 pt 2):193-8. PubMed ID: 809234
[No Abstract] [Full Text] [Related]
40. The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics.
Rifkin A; Quitkin F; Kane J; Klein DF; Ross D
Biol Psychiatry; 1979 Jun; 14(3):499-508. PubMed ID: 224958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]